Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
CAMBRIDGE, Mass., Feb. 26, 2016 -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast and conference call:
| What: | Vericel Corporation Fourth-Quarter 2015 Earnings Call | |
| When: | Monday, March 14, 2016 at 8:00am (EDT) | |
| Where: | http://investors.vcel.com/events.cfm | |
| How: | The conference call will be available live in the Investors section of the Vericel website at http://investors.vcel.com/events.cfm. Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary. | |
| To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporation fourth-quarter 2015 investor conference call. If calling from outside the U.S., please use the international phone number (253) 237- 1173. | ||
If you are unable to participate in the live call, the webcast will be available at http://investors.vcel.com/events.cfm until March 14, 2017. A replay of the call will also be available until 11:59 pm (EDT) on March 18, 2016 by calling (855) 859-2056, or from outside the U.S. (404) 537-3406. The conference ID is 55599059.
About Vericel Corporation
Vericel Corporation is a leader in developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the U.S.: Carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area. Vericel is also developing MACI™, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. For more information, please visit the company’s website at www.vcel.com.
Epicel® and Carticel® are registered trademarks and MACI™ is a trademark of Vericel Corporation. © 2016 Vericel Corporation. All rights reserved.
CONTACT: Chad Rubin The Trout Group [email protected] (646) 378-2947 or Lee Stern The Trout Group [email protected] (646) 378-2922
